Primawan Putra Nugrahadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Primawan Putra Nugrahadi has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Christian Schöneich
Department of Pharmaceutical Chemistry, University of Kansas, 2093 Constant Avenue, Lawrence, Kansas 66047, United States
1 shared publication - Christina Avanti
Department of Pharmaceutics, Faculty of Pharmacy, University of Surabaya, Surabaya, Indonesia
1 shared publication - Henderik Willem Frijlink
Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, Faculty of Science and Engineering, University of Groningen, 9713 AV Groningen, The Netherlands
1 shared publication - Wouter Leonardus Joseph Hinrichs
Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 14 March 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (3) , 935
Designing Formulation Strategies for Enhanced Stability of Therapeutic Peptides in Aqueous Solutions: A Review
Over the past few decades, there has been a tremendous increase in the utilization of therapeutic peptides. Therapeutic peptides are usually administered via the parenteral route, requiring an aqueous formulation. Unfortunately, peptides are often unstable in aqueous solutions, affecting stability and bioactivity. Although a stable and dry formulation for reconstitution might be designed, from a pharmaco-economic and practical convenience point of view, a peptide formulation in an aqueous liquid form is preferred. Designing formulation strategies that optimize peptide stability may improve bioavailability and increase therapeutic efficacy. This literature review provides an overview of various degradation pathways and formulation strategies to stabilize therapeutic peptides in aqueous solutions. First, we introduce the major peptide stability issues in liquid formulations and the degradation mechanisms. Then, we present a variety of known strategies to inhibit or slow down peptide degradation. Overall, the most practical approaches to peptide stabilization are pH optimization and selecting the appropriate type of buffer. Other practical strategies to reduce peptide degradation rates in solution are the application of co-solvency, air exclusion, viscosity enhancement, PEGylation, and using polyol excipients.
- 14 March 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (3) , 935
Top Cited PapersOpen AccessDesigning Formulation Strategies for Enhanced Stability of Therapeutic Peptides in Aqueous Solutions: A Review
Over the past few decades, there has been a tremendous increase in the utilization of therapeutic peptides. Therapeutic peptides are usually administered via the parenteral route, requiring an aqueous formulation. Unfortunately, peptides are often unstable in aqueous solutions, affecting stability and bioactivity. Although a stable and dry formulation for reconstitution might be designed, from a pharmaco-economic and practical convenience point of view, a peptide formulation in an aqueous liquid form is preferred. Designing formulation strategies that optimize peptide stability may improve bioavailability and increase therapeutic efficacy. This literature review provides an overview of various degradation pathways and formulation strategies to stabilize therapeutic peptides in aqueous solutions. First, we introduce the major peptide stability issues in liquid formulations and the degradation mechanisms. Then, we present a variety of known strategies to inhibit or slow down peptide degradation. Overall, the most practical approaches to peptide stabilization are pH optimization and selecting the appropriate type of buffer. Other practical strategies to reduce peptide degradation rates in solution are the application of co-solvency, air exclusion, viscosity enhancement, PEGylation, and using polyol excipients.